(DBVT) DBV Technologies - Overview
Stock: Viaskin Peanut, Viaskin Milk, Patch Platform, Food Allergy, Diagnostics
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 85.4% |
| Relative Tail Risk | -18.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.01 |
| Alpha | 400.29 |
| Character TTM | |
|---|---|
| Beta | 0.052 |
| Beta Downside | 0.012 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.48% |
| CAGR/Max DD | 0.23 |
Description: DBVT DBV Technologies December 30, 2025
DBV Technologies (NASDAQ:DBVT) is a French clinical-stage biopharma focused on epicutaneous immunotherapy (EPIT). Its lead asset, Viaskin Peanut, has completed a Phase 3 trial for peanut allergy, while Viaskin Milk is in Phase 1/2 for cow’s-milk protein allergy and eosinophilic esophagitis. Early-stage programs target RSV, inflammatory bowel disease, celiac disease, and type I diabetes, all built on the proprietary Viaskin patch platform. The company also partners with Nestlé Health Science on MAG1C, an at-home patch test for non-IgE-mediated cow-milk protein allergy in infants.
Key metrics as of Q3 2024: cash and cash equivalents of €115 million, runway extending beyond 2026; a market-size estimate of $5 billion for food-allergy therapeutics with a CAGR of ~10 % (source: Grand View Research, 2023); and a recent $30 million private placement that lifted its diluted share count by ~12 %, diluting but also financing the next regulatory filing. Sector-wide, the FDA’s 2022 guidance on EPIT pathways has accelerated investor interest, while European reimbursement frameworks remain a primary uncertainty for DBV’s launch strategy.
For a deeper, data-driven look at DBV’s valuation assumptions, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -125.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.89 > 0.02 and ΔFCF/TA 27.89 > 1.0 |
| NWC/Revenue: 7710 % < 20% (prev 302.4%; Δ 7407 % < -1%) |
| CFO/TA -0.89 > 3% & CFO -98.3m > Net Income -125.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.2m) vs 12m ago 0.03% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.50% > 50% (prev 13.45%; Δ -12.95% > 0%) |
| Interest Coverage Ratio: -116.1 > 6 (EBITDA TTM -115.7m / Interest Expense TTM 1.12m) |
Altman Z'' -15.00
| A: 0.36 (Total Current Assets 88.9m - Total Current Liabilities 49.5m) / Total Assets 110.5m |
| B: -3.15 (Retained Earnings -348.3m / Total Assets 110.5m) |
| C: -1.27 (EBIT TTM -129.7m / Avg Total Assets 101.8m) |
| D: -5.79 (Book Value of Equity -333.5m / Total Liabilities 57.6m) |
| Altman-Z'' Score: -22.58 = D |
Beneish M 1.00
| DSRI: 12.66 (Receivables 10.4m/20.1m, Revenue 511.0k/12.5m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.87 (AQ_t 0.05 / AQ_t-1 0.06) |
| SGI: 0.04 (Revenue 511.0k / 12.5m) |
| TATA: -0.25 (NI -125.5m - CFO -98.3m) / TA 110.5m) |
| Beneish M-Score: 5.55 (Cap -4..+1) = D |
What is the price of DBVT shares?
Over the past week, the price has changed by +2.92%, over one month by +30.63%, over three months by +63.62% and over the past year by +429.68%.
Is DBVT a buy, sell or hold?
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the DBVT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 40.3 | 81.1% |
| Analysts Target Price | 40.3 | 81.1% |
| ValueRay Target Price | 24.4 | 9.6% |
DBVT Fundamental Data Overview February 05, 2026
P/B = 23.0768
Revenue TTM = 511.0k USD
EBIT TTM = -129.7m USD
EBITDA TTM = -115.7m USD
Long Term Debt = 7.69m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 898.0k USD (from shortLongTermDebt, last quarter)
Debt = 7.80m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -69.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.16b USD (1.22b + Debt 7.80m - CCE 69.8m)
Interest Coverage Ratio = -116.1 (Ebit TTM -129.7m / Interest Expense TTM 1.12m)
EV/FCF = -11.80x (Enterprise Value 1.16b / FCF TTM -98.3m)
FCF Yield = -8.48% (FCF TTM -98.3m / Enterprise Value 1.16b)
FCF Margin = -19.2k% (FCF TTM -98.3m / Revenue TTM 511.0k)
Net Margin = -24.6k% (Net Income TTM -125.5m / Revenue TTM 511.0k)
Gross Margin = unknown ((Revenue TTM 511.0k - Cost of Revenue TTM 13.4m) / Revenue TTM)
Tobins Q-Ratio = 10.49 (Enterprise Value 1.16b / Total Assets 110.5m)
Interest Expense / Debt = 8.42% (Interest Expense 656.2k / Debt 7.80m)
Taxrate = 21.0% (US default 21%)
NOPAT = -102.5m (EBIT -129.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.80 (Total Current Assets 88.9m / Total Current Liabilities 49.5m)
Debt / Equity = 0.15 (Debt 7.80m / totalStockholderEquity, last quarter 52.9m)
Debt / EBITDA = 0.60 (negative EBITDA) (Net Debt -69.8m / EBITDA -115.7m)
Debt / FCF = 0.71 (negative FCF - burning cash) (Net Debt -69.8m / FCF TTM -98.3m)
Total Stockholder Equity = 42.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -123.3% (out of range, set to none)
RoE = -296.5% (Net Income TTM -125.5m / Total Stockholder Equity 42.3m)
RoCE = -259.3% (out of range, set to none) (EBIT -129.7m / Capital Employed (Equity 42.3m + L.T.Debt 7.69m))
RoIC = -238.4% (out of range, set to none) (NOPAT -102.5m / Invested Capital 43.0m)
WACC = 6.11% (E(1.22b)/V(1.23b) * Re(6.11%) + D(7.80m)/V(1.23b) * Rd(8.42%) * (1-Tc(0.21)))
Discount Rate = 6.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.06%
Fair Price DCF = unknown (Cash Flow -98.3m)
EPS Correlation: -22.93 | EPS CAGR: -2.56% | SUE: 0.29 | # QB: 0
Revenue Correlation: -43.15 | Revenue CAGR: -25.53% | SUE: -0.53 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.16 | Chg30d=+0.062 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.46 | Chg30d=+0.105 | Revisions Net=+1 | Growth EPS=+46.4% | Growth Revenue=-24.1%